ReShape Lifesciences Inc. (RSLS)

0.1653 -0.0071 (-4.12%) At close: 04:00PM EDT

ReShape Lifesciences Inc.

1001 Calle Amanecer
San Clemente, CA 92673
United States
949 429 6680
https://www.reshapelifesciences.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 29

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Dan W. Gladney	Executive Chair	129.5k	N/A	1953
Mr. Paul F. Hickey	CEO, President & Director	506.42k	N/A	1965
Mr. Thomas Stankovich	Senior VP & CFO	307.12k	N/A	1961
Dr. Mark B. Knudson Ph.D.	Co-Founder and Special Advisor to the CEO	33k	N/A	1949
Dr. Katherine S. Tweden Ph.D.	Co-Founder	338.41k	N/A	1961
Mr. Al Diaz	Vice President of Operations and R&D	N/A	N/A	N/A
Dr. Dov Gal D.V.M., M.B.A.	VP of Regulatory Clinical Quality & Compliance Officer	N/A	N/A	N/A
Jody B. Dahlman	Director of Communications	N/A	N/A	N/A
Mr. Naqeeb A. Ansari	Senior Vice President of Global Commercial Operations	327.46k	N/A	1961

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

Corporate governance

ReShape Lifesciences Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.